GC Green Cross Holds Groundbreaking Ceremony for Indonesian Blood Product Factory... "Targeting Operation in 2027"

Annual Processing of Up to 400,000ℓ Plasma

GC Green Cross announced on the 6th that it held a groundbreaking ceremony for a blood product plant in the Jababeka Industrial Complex near Jakarta, Indonesia.

GC Green Cross announced on the 6th that it attended the groundbreaking ceremony for a blood product plant held at the Jababeka Industrial Complex near Jakarta, Indonesia. Attendees including Park Soo-deok, Charg? d'Affaires of the Embassy of the Republic of Korea in Indonesia; Nanik Gunawan, CEO of pharmaceutical company Medquest; Budi Gunadi Sadikin, Minister of Health; Muhammad Yusuf Kala, President of the Red Cross; Triman James Setia Darma of the pharmaceutical company; Heo Eun-cheol, CEO of GC Green Cross; and Nonen Komara Engsi, representative of the West Java Industrial Complex, are taking a commemorative photo. (From the left)
Photo by GC Green Cross

This comes about six months after GC Green Cross acquired the plant construction project rights last June, and the groundbreaking was made possible with active support from both the Korean and Indonesian governments. This groundbreaking marks the first blood product factory construction in Indonesia.

Sponsored by the Indonesian Ministry of Health, the ceremony was attended by about 150 people, including GC Green Cross CEO Heo Eun-cheol, GC Green Cross EM CEO Park Chung-kwon, Indonesian Minister of Health Budi Gunadi Sadikin, Indonesian Red Cross President Muhammad Yusuf Kala, and Park Soo-duk, Charg? d'Affaires of the Embassy of the Republic of Korea in Indonesia.

The new plant will be built on a 40,000㎡ site within the Jababeka Industrial Complex, approximately 35 km east of Jakarta, the capital of Indonesia. The site is capable of processing up to 400,000 liters of raw plasma annually, with operations targeted to begin in 2027.

GC Green Cross explained that since this groundbreaking signals the start of local production of blood products, which Indonesia has relied entirely on imports for as essential national medicines, many government officials participated to show their support.

Heo Eun-cheol, CEO of GC Green Cross, said, "We are pleased and honored to take the historic first step toward the localization of blood products, which the Indonesian people have long wished for, together with GC Green Cross. Starting with the successful completion of the plant construction, we will expand cooperation and support for the development of Indonesia's medical and healthcare industry."

Meanwhile, GC Green Cross received approval from the Indonesian Ministry of Health and Welfare last June for the project rights related to the construction and technology transfer of the blood product plant. Subsequently, a tripartite memorandum of understanding was signed with the Indonesian Red Cross and pharmaceutical companies. The Indonesian government selected GC Green Cross as the preferred negotiator for the blood product plant construction and technology transfer project rights in January and approved GC Green Cross as the project operator after detailed consultations and coordination.

Currently, GC Green Cross is the only company worldwide that has successfully exported blood product plants. GC Green Cross not only was the first domestic pharmaceutical company to export a blood product plant to Thailand but also has experience and know-how in building factories in various countries such as China and Canada. Since the 1970s, starting with albumin, GC Green Cross has produced various blood products and completed the Ochang plant, the largest blood product factory in Asia, in 2009. It currently exports 12 items to 32 countries, continuing its blood product business.